Health Canada Approves Cyclotron Produced Technetium-99m utilizing the ARTMS QIS™ and Solid Targets

ARTMS Inc. (ARTMS) is excited to announce Health Canada’s marketing approval of cyclotron produced technetium-99m (99mTc) for clinical use. For the Health Canada submission, ARTMS provided technical expertise and the solid targets required for production to a Canadian consortium consisting of BC Cancer, TRIUMF, Lawson Health Research and the Centre for Probe Development and Commercialization. The process was approved by Health Canada on November 26, 2020 and is being deployed immediately. (read more)

This entry was posted in Uncategorized. Bookmark the permalink. Comments are closed, but you can leave a trackback: Trackback URL.